Monday, July 22, 2013
Forced by government and
societal pressures to release clinical trial data - and caught between
competing desires for open and restricted access - EMA has crafted a
compromise policy that may not satisfy all the stakeholders but at least will
fit within its existing regulatory framework.
The EU Parliament, Ombudsman
and European member states have been applying political pressure for increased
data transparency, and publishers, academics and patient advocates have been
pushing an agenda of unqualified open access.